Pol F. Boudes
Equibles does not estimate personal net worth.
About Pol F. Boudes
Galectin Therapeutics Inc reported in an 8-K filed August 1, 2024 that Pol F. Boudes resigned as Chief Medical Officer, effective July 26, 2024. The proxy statement of Galectin Therapeutics Inc reports total compensation of $770,280 for Pol F. Boudes in fiscal 2023, including a base salary of $530,000. Disclosed compensation is on record for 4 fiscal years.
“Dr. Jamil succeeds Dr. Pol Boudes as Chief Medical Officer of the Company, who resigned on July 26, 2024.”
Affiliation history
-
Galectin Therapeutics Inc (GALT)
Proxy statement
Start not stated–2024-12-03
Last confirmed by a filing; no departure on record
-
Galectin Therapeutics Inc (GALT)
Proxy statement
Start not stated–2024-07-26
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Galectin Therapeutics Inc (GALT) | M.D., Former Chief Medical Officer | $530,000 | $770,280 |
| 2022 | Galectin Therapeutics Inc (GALT) | M.D., Former Chief Medical Officer | $473,333 | $794,577 |
| 2021 | Galectin Therapeutics Inc (GALT) | M.D., Chief Medical Officer | $452,583 | $923,683 |
| 2020 | Galectin Therapeutics Inc (GALT) | M.D., Chief Medical Officer | $367,083 | $1,082,481 |